| | |
| Clinical data | |
|---|---|
| Other names | Solengepras; CVN-424; CVN424 |
| Routes of administration | Oral [1] |
| Drug class | GPR6 inverse agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H29F2N5O3 |
| Molar mass | 473.525 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Solangepras (INN ; developmental code name CVN-424), or solengepras (USAN ), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease. [1] [2] [3] [4] It is a small molecule and is taken by mouth. [1] [4] Solangepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents. [4] It is being developed by Cerevance. [1] [2] As of October 2024, solangepras is in phase 3 clinical trials. [1] [2]